Emergent Human Immunodeficiency Virus Type 1 (HIV-1) Drug Resistance in Randomized Trials of Contemporary Antiretroviral Regimens
Por:
Llibre, JM, Ripamonti, D, Geretti, AM, Martin-Iguacel, R, Sax, PE, Gupta, RK, Shafer, RW, Schapiro, JM, Kuritzkes, DR and Mesplède, T
Publicada:
15 may 2026
Ahead of Print:
1 sep 2025
Resumen:
The occurrence of virological failure in a subset of individuals is an inevitable aspect of antiretroviral treatment, and historically has been primarily influenced by suboptimal adherence to oral therapies. The risk of selecting 1- or 2-class human immunodeficiency virus (HIV) drug resistance is influenced by the composition of the regimen, differing significantly depending on the intrinsic barrier to resistance of the regimen. HIV resistance emergence during treatment can be viewed as a regimen-related adverse effect that warrants equal consideration in clinical trials alongside virological and safety endpoints. Antiretroviral regimens demonstrating non-inferiority and showing similar rates of virological failure can nonetheless differ in terms of HIV emergent resistance. We propose the development of a systematic framework to categorize emergent HIV drug resistance in clinical trials. Standardizing the evaluation of resistance in clinical trials and its reporting to regulatory agencies will facilitate an improved understanding of regimen-specific resistance risks and better inform clinical decision making.
The intrinsic barrier to resistance of an antiretroviral regimen modulates the emergent HIV resistance during virological failure episodes. HIV resistance emergence during treatment warrants consideration in randomized clinical trials equivalent to virological and safety endpoints and should be standardized.
Filiaciones:
:
Univ Hosp Germans Trias, Div & Fight Infect Fdn, Infect Dis, Badalona, Barcelona, Spain
CIBER Epidemiol & Publ Hlth CIBERESP, Madrid, Spain
Ripamonti, D:
ASST Papa Giovanni XXIII, Infect Dis Unit, Bergamo, Italy
Geretti, AM:
Univ Roma Tor Vergata, Dept Syst Med, Infect Dis Unit, Rome, Italy
Royal Free London NHS Trust, Dept HIV Med, London, England
Martin-Iguacel, R:
Odense Univ Hosp, Dept Infect Dis, Odense, Denmark
Ctr Epidemiol Studies HIV AIDS & STI Catalonia CEE, Badalona, Spain
Sax, PE:
Harvard Med Sch, Brigham & Womens Hosp, Div Infect Dis, Boston, MA USA
Gupta, RK:
Univ Cambridge, Dept Med, Cambridge, England
Africa Hlth Res Inst, Kwa Zulu, South Africa
Shafer, RW:
Stanford Univ, Med Sch, Infect Dis, Stanford, CA USA
Schapiro, JM:
Sheba Med Ctr, Natl Hemophilia Ctr, Tel Aviv, Israel
Kuritzkes, DR:
Harvard Med Sch, Brigham & Womens Hosp, Div Infect Dis, Boston, MA USA
Mesplède, T:
Erasmus Univ, Virosci Dept, Med Ctr, Rotterdam, Netherlands
Green Published
|